Bupropion/naltrexone - Nalpropion Pharmaceuticals

Drug Profile

Bupropion/naltrexone - Nalpropion Pharmaceuticals

Alternative Names: Bupropion/naltrexone; Contrave; Mysimba; Naltrexone HCl/ bupropion HCl prolonged release; Naltrexone HCl/bupropion HCl; Naltrexone HCl/bupropion HCl extended release; Naltrexone SR/bupropion SR; Naltrexone XR/bupropion XR; Naltrexone/bupropion; NB32

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orexigen Therapeutics
  • Developer Bausch Health Companies; Biologix FZCo; Kwang Dong Pharmaceutical; Orexigen Therapeutics; Rovi
  • Class Analgesics; Antidepressants; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphine derivatives; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Opioid mu receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Marketed Obesity
  • No development reported Depressive disorders; Smoking withdrawal

Most Recent Events

  • 30 Jul 2018 Bupropion/naltrexone market licensed to Pernix Therapeutics Holdings in USA
  • 30 Jul 2018 Nalpropion Pharmaceuticals acquires bupropion/naltrexone from Orexigen Therapeutics
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top